Compare · DHR vs GBS
DHR vs GBS
Side-by-side comparison of Danaher Corporation (DHR) and GBS Inc. (GBS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DHR and GBS operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- DHR carries a market cap of $158.84B.
- DHR has hit the wire 23 times in the past 4 weeks while GBS has been quiet.
- DHR has more recent analyst coverage (25 ratings vs 0 for GBS).
- Company
- Danaher Corporation
- GBS Inc.
- Price
- -
- -
- Market cap
- $158.84B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 23
- 0
- Recent ratings
- 25
- 0
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
GBS Inc.
GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest DHR
- Executive Vice President Gregory M Milosevich covered exercise/tax liability with 58 shares, decreasing direct ownership by 0.26% to 22,309 units (SEC Form 4)
- SVP-Chief Legal Officer Jonathan Leiken covered exercise/tax liability with 1,122 shares, decreasing direct ownership by 9% to 11,424 units (SEC Form 4)
- President & CEO Sawyer Montgomery Julie A covered exercise/tax liability with 261 shares, decreasing direct ownership by 1% to 21,960 units (SEC Form 4)
- SVP, Chief Strategy Officer Shashanka Muppaneni covered exercise/tax liability with 122 shares, decreasing direct ownership by 2% to 5,779 units (SEC Form 4)
- EVP & Chief Financial Officer Matthew E Gugino covered exercise/tax liability with 1,018 shares, decreasing direct ownership by 9% to 10,383 units (SEC Form 4)
- Director Daniel L Comas was granted 282 shares (SEC Form 4)
- SVP, Chief HR Officer Heathre T Moler covered exercise/tax liability with 37 shares, decreasing direct ownership by 0.69% to 5,319 units (SEC Form 4)
- Director Robert Hershberg was granted 282 shares (SEC Form 4)
- Executive Vice President Milosevich Gregory M sold $484,302 worth of shares (2,100 units at $230.62), decreasing direct ownership by 9% to 22,367 units (SEC Form 4)
- Executive Vice President Mcgrew Matthew exercised 17,385 shares at a strike of $88.24 and sold $4,097,452 worth of shares (17,385 units at $235.69) (SEC Form 4)
Latest GBS
- SEC Form SC 13G/A filed by GBS Inc. (Amendment)
- SEC Form SC 13G/A filed by GBS Inc. (Amendment)
- SEC Form 8-K filed by GBS Inc.
- SEC Form 10-Q filed by GBS Inc.
- GBS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by GBS Inc. (Amendment)
- GBS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GBS Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- GBS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by GBS Inc.